KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Operating Leases: 2019-2024

Historic Operating Leases for Esperion Therapeutics (ESPR) over the last 6 years, with Dec 2024 value amounting to $2.6 million.

  • Esperion Therapeutics' Operating Leases fell 76.75% to $767,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $767,000, marking a year-over-year decrease of 76.75%. This contributed to the annual value of $2.6 million for FY2024, which is 14.90% down from last year.
  • Latest data reveals that Esperion Therapeutics reported Operating Leases of $2.6 million as of FY2024, which was down 14.90% from $3.0 million recorded in FY2023.
  • In the past 5 years, Esperion Therapeutics' Operating Leases registered a high of $3.5 million during FY2020, and its lowest value of $524,000 during FY2021.
  • Its 3-year average for Operating Leases is $2.1 million, with a median of $2.6 million in 2024.
  • Per our database at Business Quant, Esperion Therapeutics' Operating Leases tumbled by 84.83% in 2021 and then spiked by 354.14% in 2023.
  • Over the past 5 years, Esperion Therapeutics' Operating Leases (Yearly) stood at $3.5 million in 2020, then crashed by 84.83% to $524,000 in 2021, then climbed by 26.91% to $665,000 in 2022, then soared by 354.14% to $3.0 million in 2023, then declined by 14.90% to $2.6 million in 2024.